Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Progress Report On UK's Early Access Scheme: A Limited Success But Could Do Better

This article was originally published in SRA

Executive Summary

The UK's early access to medicines scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed. Sten Stovall talks to those in the industry that have first-hand experience of the process.

Advertisement

Related Content

UK Accelerated Access Proposals Due Out Soon
Advertisement
UsernamePublicRestriction

Register

PS118632

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel